The September 15 short interest data have been compared with the previous report, and short interest moves were upward across most of these selected biotech stocks.
An RBC report noted that although headline issues such as the Federal Reserve and the election are increasing volatility, four top biotech companies may be a solid play now.
Agios Pharmaceuticals has filed with the SEC regarding a secondary offering of up to $150 million of its common stock.
Chris Lange The August 31 short interest data have been compared with the previous report, and short interest decreased for most of these selected biotech stocks.
Some biotech companies made impressive runs over the course of this past week. These select few stood out from the rest.
Celgene is making a move out of left field that has sent shares of its partner Agios Pharmaceuticals significantly higher.
Chris Lange The August 15 short interest data have been compared with the previous report, and short interest moves were mixed across these selected biotech stocks.
Medivation has been among the top future biotech mergers for quite some time. The problem is that we still have no idea which company will buy Medivation, nor do we know what…
Jefferies searches for growth with reasonable valuations and upside potential. This week's picks are no exception to that rule.
The short interest data are out for the July 29 settlement date and short interest decreased across these selected biotech stocks.
Though these four large cap biotech stocks are cheap relative to the S&P 500, history says they won’t stay that way.
The top analyst upgrades, downgrades and initiations seen on Thursday morning include Apollo Global, ADM, Celgene, Total, Whole Foods and Targa Resources.
Finally, concerns about biotech seem to be waning. An RBC research report notes that at the recent political conventions there was little to no mention of drug pricing.
Overall, investors were content after Celgene reported its second-quarter financial results, with wins on both the top and bottom lines.
Chris Lange A new JPMorgan research report says it time to buy the health care sector and sell consumer staples, which have run hard this year.
